From www.LEF.org
Resveratrol helps cancer cells overcome resistance to common drug
Feb 21, 2011
An article published in the February 28, 2011 issue of the journal Cancer Letters reports the finding of researchers at Ohio’s Cleveland Clinic of a benefit for resveratrol in suppressing the growth of breast cancer tumor cells that have become resistant to the drug rapamycin, an immunosuppression drug that has been used to treat cancer. Results from other research involving resveratrol, a compound found in red wine, grapes and other plant foods, suggest an anticancer effect for several types of malignancies.
A team led by Charis Eng, MD, PhD, who is the Chair of the Genomic Medicine Institute of Cleveland Clinic’s Lerner Research Institute tested the effect of resveratrol and rapamycin separately and in varying combinations on three human breast cancer cell lines. They found dose-dependent effects for both compounds and an additive effect for a combination of the two, which induced 50 percent growth inhibition in all lines when administered in low concentrations. It was determined that a tumor suppressing gene known as PTEN contributes to resveratrol’s growth suppressive effects.
"Rapamycin has been used in clinical trials as a cancer treatment,” Dr Eng stated. “Unfortunately, after a while, the cancer cells develop resistance to rapamycin."
Resveratrol helps cancer cells overcome resistance to common drug
Feb 21, 2011
An article published in the February 28, 2011 issue of the journal Cancer Letters reports the finding of researchers at Ohio’s Cleveland Clinic of a benefit for resveratrol in suppressing the growth of breast cancer tumor cells that have become resistant to the drug rapamycin, an immunosuppression drug that has been used to treat cancer. Results from other research involving resveratrol, a compound found in red wine, grapes and other plant foods, suggest an anticancer effect for several types of malignancies.
A team led by Charis Eng, MD, PhD, who is the Chair of the Genomic Medicine Institute of Cleveland Clinic’s Lerner Research Institute tested the effect of resveratrol and rapamycin separately and in varying combinations on three human breast cancer cell lines. They found dose-dependent effects for both compounds and an additive effect for a combination of the two, which induced 50 percent growth inhibition in all lines when administered in low concentrations. It was determined that a tumor suppressing gene known as PTEN contributes to resveratrol’s growth suppressive effects.
"Rapamycin has been used in clinical trials as a cancer treatment,” Dr Eng stated. “Unfortunately, after a while, the cancer cells develop resistance to rapamycin."
"Our findings show that resveratrol seems to mitigate rapamycin-induced drug resistance in breast cancers, at least in the laboratory,” she reported. “ If these observations hold true in the clinic setting, then enjoying a glass of red wine or eating a bowl of boiled peanuts – which has a higher resveratrol content than red wine – before rapamycin treatment for cancer might be a prudent approach."
For more information about Resveratrol click here
For more information about Resveratrol click here
No comments:
Post a Comment